US-based laboratory services provider Labcorp has acquired select assets of North Mississippi Health Services’ (NMHS) ambulatory outreach laboratory business, enhancing its presence in the region.
Labcorp will serve as the referral laboratory for NMHS’s seven hospitals and clinic laboratories, ensuring continuity of laboratory services for patients and providers.
The acquisition will provide NMHS’s patients and providers with access to Labcorp’s advanced clinical laboratory services, data, and digital tools.
In addition, Labcorp is planning to open three new patient service centres in Amory, Tupelo, and West Point by mid-year, to further increase service availability.
Labcorp Southeast Division senior vice president Lenny Monsour said: “Labcorp is committed to continuing the longstanding tradition of high-quality laboratory and healthcare services that North Mississippi Health Services’ patients have come to expect and deserve while increasing access to these important services, especially for those living in rural communities.
“The acquisition allows us to leverage the strengths of both organisations to positively impact healthcare for communities in North Mississippi.”
NMHS operates in 24 counties across north Mississippi and northwest Alabama, offering a range of services including acute, diagnostic, therapeutic, and emergency care.
Its flagship hospital, North Mississippi Medical Center in Tupelo, houses the area’s sole Level 2 trauma centre.
Both organisations have collaborated to ensure a seamless transition, maintaining service continuity for patients, hospitals, physicians, and clients.
Labcorp said the acquisition aligns with its strategy of collaborating with local and regional health systems to enhance patient and provider services.
NMHS president and CEO Shane Spees said: “North Mississippi Health Services will continue to operate laboratories in each of our hospitals and clinics with this partnership helping to address key pieces of our strategy, including improving access, evolving how we ‘do the work’ and creating alternative revenue sources.”
Earlier this month, Labcorp launched the pTau-217/Beta Amyloid 42 Ratio test nationwide, a blood-based biomarker test designed to aid in diagnosing Alzheimer’s disease.
The addition strengthens Labcorp’s portfolio of blood-based biomarkers for the detection of Alzheimer’s disease and dementia.
